Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Post by Treeshon Nov 27, 2021 1:52pm
434 Views
Post# 34172344

Thoughts on this?

Thoughts on this?
Posted by Camilo Ricordi this morning:

“It’s a remarkable time for T1D research efforts worldwide as this investigational treatment enters the clinic,” said Camillo Ricordi, M.D., Professor of Surgery, Director of the Diabetes Research Institute and the Cell Transplant Center at the University of Miami Miller School of Medicine, Steering Committee Chair for the VX-880 clinical trial and Principal Investigator at the University of Miami Health System clinical site. “The field’s experience with the limited cadaveric islet transplants available, where some patients have experienced prolonged insulin independence for years, provides important proof-of-concept for the potential of cell therapy to be transformative for patients living with T1D.”
 
Mr. Shelton was the first patient. On June 29, he got an infusion of cells, grown from stem cells but just like the insulin-producing pancreas cells his body lacked.
 
Now his body automatically controls its insulin and blood sugar levels.
 
Mr. Shelton, now 64, may be the first person cured of the disease with a new treatment that has experts daring to hope that help may be coming for many of the 1.5 million Americans suffering from Type 1 diabetes.
 
“It’s a whole new life,” Mr. Shelton said. “It’s like a miracle.”
 
This was first base to possibly solve the challenge of developing an unlimited supply of insulin producing cells … now if you combine it with a technology that could eliminate the need for chronic immunosuppression of the recipients (www.iTolerance.com) and we could have the long waited home run - Camillo Ricordi
 
Now more than ever, let’s keep focused on a biologic cure without anti rejection drugs !!!  
 
https://www.nytimes.com/2021/11/27/health/diabetes-cure-stem-cells.html?referringSource=articleShare
 
#diabetes #cure #diabetesresearch #stemcell #stemcelltherapy
<< Previous
Bullboard Posts
Next >>